


## Supplementary Materials


### Supplementary Figure S1



#### Supplementary Figure S1. Effects of Pgp ligands on mitoxantrone permeability across BBB

hCMEC/D3 cells were grown in the upper insert of Transwell devices for 7 days, then medium was replaced with fresh medium (ctrl) or with medium containing 1 nM of compounds **1-6** for 24 h. 10  $\mu$ M mitoxantrone (MXR) was added in the last 3 h. The amount of mitoxantrone in the medium of the lower chamber was measured spectrofluorimetrically, in duplicates. Data are presented as means  $\pm$  SD (n = 3).


## Supplementary Figure S2



### Supplementary Figure S2. Effects of MRP1 and BCRP inhibitors on doxorubicin transport across BBB

hCMEC/D3 cells were grown in the upper insert of Transwell devices for 7 days, then medium was replaced with fresh medium (ctrl) or with medium containing 1 nM of compounds **1-6** for 24 h. 5  $\mu$ M doxorubicin (doxo) was added during the last 3 h, in the presence of 25  $\mu$ M MK571, an inhibitor of MRP1, or 5  $\mu$ M fumitremorgin C (Fumi), an inhibitor of BCRP. The amount of doxorubicin in the medium of the lower chamber was measured spectrofluorimetrically, in duplicates. Data are presented as means  $\pm$  SD (n = 3). Versus doxo: \* p < 0.01.

## Supplementary Figure S3




### Supplementary Figure S3. Effects of Pgp ligands on doxorubicin transport in Pgp-MDCK, MRP1-MDCK and BCRP-MDCK cells

**A.** MDCK, Pgp-MDCK, MRP1-MDCK, BCRP-MDCK cells were lysed and immunoblotted with the indicated antibodies.  $\beta$ -tubulin level was used as control of equal protein loading. The figure is representative of one out of three experiments with similar results. **B-D.** Pgp-MDCK (panel **B**), MRP1-MDCK (panel **C**), BCRP-MDCK (panel **D**) cells were grown in the upper insert of Transwell devices for 7 days, then medium was replaced with fresh medium (ctrl) or with medium containing 1 nM of compounds **1-6** for 24 h. 5  $\mu$ M doxorubicin (doxo) was added during the last 3 h. When indicated, 50  $\mu$ M verapamil (ver), an inhibitor of Pgp, 25  $\mu$ M MK571, an inhibitor of MRP1, or 5  $\mu$ M fumitremorgin C (Fumi), an inhibitor of BCRP were added. The amount of

doxorubicin in the medium of the lower chamber was measured spectrofluorimetrically, in duplicates. Data are presented as means  $\pm$  SD (n = 3). Versus doxo: \* p < 0.05; doxo+ver/doxo+MK571/dox+Fumi vs doxo:° p < 0.001.

## Supplementary Figure S4



### Supplementary Figure S4. Effects of Pgp ligands on dextran, sucrose, inulin and lucifer yellow permeability across BBB

hCMEC/D3 cells were grown in the upper insert of Transwell devices for 7 days, then medium was replaced with fresh medium (ctrl) or with medium containing 1 nM of compounds **1-6** for 24 h. 2  $\mu$ M dextran-FITC (panel **A**), 2  $\mu$ Ci/ml [ $^{14}$ C]-sucrose (panel **B**), 2  $\mu$ Ci/ml [ $^{14}$ C]-inulin (panel **C**), 100  $\mu$ M lucifer yellow (panel **D**) were added in the last 3 h. The amount of each compound in the medium of the lower chamber was measured spectrofluorimetrically (for dextran-FITC and luciferin yellow) or by liquid scintillation (for [ $^{14}$ C]-sucrose and [ $^{14}$ C]-inulin), in duplicates. Data are presented as means  $\pm$  SD (n = 3).

**Supplementary Table S1. Phenotypic characterization of cells from patient number 1, 2, 3 by immunofluorescence analysis**

	NS	NS	NS	AC	AC	AC
Marker	CV17	010627	Nov3	CV17	010627	Nov3
<b>Nestin</b>	++	+	+	+	-	-
<b>CD133</b>	+	+	+	-	-	-
<b>Musashi</b>	+	+	+	-	-	-
<b>SOX2</b>	+	+	+	-	-	-
<b>EGFR</b>	+/-	+	+	+	-	-
<b>p53</b>	+	+	+	-	-	-
<b>GFAP</b>	-	-	-	+	+	+
<b>GalC</b>	+	-	-	+	+/-	++